Virax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interest

Virax Biolabs Group Limited (VRAX) is up 177.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears primarily driven by micro-cap momentum and short-squeeze dynamics rather than a fresh fundamental update from the company. With unusually high reported short interest versus its public float, incremental buying can translate into outsized percentage gains as shorts cover and liquidity thins.

Details:

Recent short-interest data indicated shares sold short exceeded the reported public float by a wide margin, a setup that can amplify upside when price starts running.

A Schedule 13G/A filed May 15, 2026 showed Armistice Capital reporting beneficial ownership of 1,000,239 shares (4.99% of the class), which can be interpreted by traders as a sign of institutional positioning.

The company’s most recent investor communications (March–April 2026) highlighted progress milestones for its ViraxImmune program and steps toward regulated diagnostics development, which may have helped keep attention on the name despite no clear same-day press release.

This could also be exacerbated by retail-driven trading in a very small-cap stock, where rapid price changes can occur on elevated volume.

Sources:

Virax Biolabs Investor Relations, MarketBeat, ORTEX

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VRAX Hedge Fund Activity

We have seen 2 institutional investors add shares of $VRAX stock to their portfolio, and 5 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARMISTICE CAPITAL, LLC added 878,803 shares (+inf%) to their portfolio in Q1 2026, for an estimated $193,248
HRT FINANCIAL LP removed 60,073 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $20,773
JUMP FINANCIAL, LLC added 40,724 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,955
XTX TOPCO LTD removed 21,437 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,713
VIRTU FINANCIAL LLC removed 21,376 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,391
UBS GROUP AG removed 7,492 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,647
NATIONAL BANK OF CANADA /FI/ removed 6,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,319

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VRAX Analyst Ratings

Wall Street analysts have issued reports on $VRAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 01/09/2026

To track analyst ratings and price targets for $VRAX, check out Quiver Quantitative's $VRAX forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.